A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3045697 AFTER SINGLE ORAL DOSING IN HEALTHY SUBJECTS

A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3045697 AFTER SINGLE ORAL DOSING IN HEALTHY SUBJECTS - ASEA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38917

Enrollment

Registered

2012-12-19

Start date

2013-01-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease Kidney Disease

Interventions

Single oral dose of LY3045697 or placebo

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Healthy males or females (postmenopausal or surgically sterile) -Postmenopausal female subjects must be between the ages of 45 and 65 years, inclusive -Male subjects and surgically sterile females must be between the ages of 18 and 65 years, inclusive -BMI between 18.0 and 32.5 kg/m2 , inclusive

Exclusion criteria

Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
Safety and tollerability of LY3045697	—

Secondary

Measure	Time frame
Pharmacokinetics of LY3045697	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)